%A Kurdi,Maher %A Shafique Butt,Nadeem %A Baeesa,Saleh %A Alghamdi,Badrah %A Maghrabi,Yazid %A Bardeesi,Anas %A Saeedi,Rothaina %A Al-Sinani,Taghreed %A Alghanmi,Najla %A Bari,Mohammed %A Samkari,Alaa %A Lary,Ahmed %D 2021 %J Pathology and Oncology Research %C %F %G English %K Glioblastoma,chemotherapy,IDH1 mutation,MGMT promoter methylation,Radiotherapy %Q %R 10.3389/pore.2021.1609778 %W %L %M %P %7 %8 2021-April-29 %9 Original Research %+ Mx Maher Kurdi,King Abdulaziz University,Jeddah,21589,Makkah,Saudi Arabia,Ahkurdi@kau.edu.sa %# %! IDH1 mutation and MGMT methylation in Glioblastoma %* %< %T The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents %U https://www.por-journal.com/articles/10.3389/pore.2021.1609778 %V 27 %0 JOURNAL ARTICLE %@ 1532-2807 %X The aim of this study is to investigate the relationship between isocitrate dehydrogenase-1 (IDH1) mutation and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with recurrence-free interval in glioblastoma patients treated with chemoradiotherapies. Clinical data were collected from 82 patients with totally resected glioblastoma and treated with adjuvant therapies from 2014 to 2019. IDH1 mutation was assessed by immunohistochemistry and MGMT promoter methylation was assessed by different sequencing methods. IDH1 mutation was present in 32 cases and 50 cases were IDH1 wildtype; 54 and 28 patients had unmethylated and methylated MGMT promoter, respectively, Of the 82 patients, 62 patients received chemoradiotherapy while 20 patients only received radiation. Approximately, 61% of patients had a tumor recurrence after 1 year, and 39% showed a recurrence before 1 year of treatment. There was no significant relationship between IDH1 mutation and MGMT promoter methylation (p-value = 0.972). Patients with IDH1 mutation and their age <50 years showed a significant difference in recurrence-free interval (p-value = 0.014). Difference in recurrence-free interval was also statistically observed in patients with unmethylated MGMT promoter and treated with chemoradiotherapies (p-value = 0.031), by which they showed a late tumor recurrence (p-value = 0.016). This revealed that IDH1 mutation and MGMT methylation are independent prognostic factors in glioblastoma. Although IDH1-mutant glioblastomas showed late tumor recurrence in patients less than 50 years old, the type of treatment modalities may not show additional beneficial outcome. Patients with unmethylated MGMT and IDH1 mutation, treated with different chemoradiotherapies, showed a late tumor recurrence.